Dovedi SJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74:5458-5468.
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020-2031.
Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus platinum doublet chemotherapy and concurrent radiotherapy as first-line therapy for unresectable, locally advanced stage iii NSCLC: KEYNOTE-799. J Clin Oncol. 2020;38(15 suppl): Abstract 9008.
Juergens RA, Hao D, Ellis PM, et al. A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. Lung Cancer. 2020;143:1-11.
Kelly K, Daly ME, Mirhadi A, et al. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer. J Clin Oncol. 2020;38(15 suppl): Abstract 9011.
Leighl NB, Laurie SA, Goss GD, et al. CCTG BR.34: A randomized trial of durvalumab and tremelimumab ± platinum-based chemotherapy in patients with metastatic (stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(15 suppl): Abstract 9502.
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040-2051.
Ramalingam SS, Ciuleanu T-E, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 Part 1 . J Clin Oncol. 2020;38(15 suppl): Abstract 9500.
Reck M, Ciuleanu T-E , Cobo M, et al. Nivolumab + ipilimumab + 2 cycles of platinum‐doublet chemotherapy vs 4 cycles chemotherapy as first-line treatment for stage IV/recurrent NSCLC: CheckMate 9LA. J Clin Oncol. 2020;38(15 suppl): Abstract 9501.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6:661-674.
Rodríguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38(15 suppl): Abstract 9503.
Rodríguez-Abreu D, Powell SF, Hochmair M, et al. Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2020;38(15 suppl): Abstract 9582.
Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
Timmerman R., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-1076.
West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924-937.
Young KH, et al. Optimizing timing of immunotherapy improves vontrol of tumors by hypofractionated radiation therapy. PLoSOne. 2016;11:e0157164.

CME / ABIM MOC

Immunotherapy Strategies for the Treatment of NSCLC: An Update From Virtual Chicago

Authors: Karen Kelly, MD; Natasha Leighl, MD, MMSc, FRCPC, FASCO; Suresh S. Ramalingam, MD; Martin Reck, MD, PhD; Delvys Rodríguez-Abreu, MD
CME / ABIM MOC Released: 10/22/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/22/2021, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, and surgeons.

The goal of this activity is to increase awareness of the latest data on immunotherapies under study for non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest clinical trial data investigating immunotherapy strategies in NSCLC
Demonstrate greater confidence in their ability to
- Interpret the latest clinical trial data investigating immunotherapy strategies in NSCLC

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Karen Kelly, MD

Professor of Medicine
Associate Director for Clinical Research
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, California, United States

Disclosures

Disclosure: Karen Kelly, MD, has disclosed no relevant financial relationships.

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Professor of Medicine
Department of Medicine and IHPME
Medical Oncology Lung Site Lead
Princess Margaret Cancer Centre
University of Toronto
Toronto, Canada

Disclosures

Disclosure: Natasha Leighl, MD, MMSc, FRCPC, FASCO, has disclosed the following relevant financial relationships:
Received grants for clinical research from: ArrAY; AstraZeneca; Eli Lilly’ Guardant; MSD; Pfizer; Roche

Suresh S. Ramalingam, MD

Professor, Hematology & Medical Oncology
Deputy Director
Winship Cancer Institute
Emory University
Atlanta, Georgia, United States
The opinions expressed are those of Dr Ramalingam and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Ramalingam’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosures

Disclosure: Suresh S. Ramalingam, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Bristol Myers Squibb Company; GlaxoSmithKline; Lilly; Merck; Takeda
Received grants for clinical research from: Amgen; Advaxis; AstraZeneca; Bristol Myers Squibb Company; Genmab; Merck; Takeda

Martin Reck, MD, PhD

Professor of Medicine
Department of Thoracic Oncology
LungenClinic Grosshansdorf
Schleswig-Holstein, Germany

Disclosures

Disclosure: Martin Reck, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim; Lilly; Merck; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche; Samsung
Served as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Bristol Myers Squibb Company; Boehringer Ingelheim; Lilly; Merck; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche; Samsung

Delvys Rodríguez-Abreu, MD

Medical Oncologist
Hospital Universitario Insular de Gran Canaria
Gran Canaria, Spain

Disclosures

Disclosure: Delvys Rodriguez-Abreu, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; Bristol Myers Squibb Company; Lilly; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Bristol Myers Squibb; Lilly; Merck Sharp & Dohme, Corp.; Novartis; Pfizer; Roche
Received grants for clinical research from: Bristol Myers Squibb Company

Editor

Charlotte Warren

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

Course Director

Marina Chiara Garassino, MD

Chief of Thoracic Oncology Unit
Istituto Nazionale dei Tumori di Milano
Medical Oncology and Hematology Department
Milan, Italy

Disclosures

Disclosure: Marina Chiara Garassino, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Incyte Corporation; MedImmune; MSD Oncology; Roche; Seattle Genetics, Inc.; Takeda Pharmaceuticals North America, Inc.; Tiziana Life Sciences
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Incyte Corporation; MSD Oncology; Roche; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Blueprint Medicines; Bristol-Myers Squibb Company; Genentech; GlaxoSmithKline; Incyte Corporation; MedImmune; Merck; MSD, Pfizer; Novartis; Roche; Spectrum Pharmaceuticals, Takeda Pharmaceuticals North America, Inc.
Other: AstraZeneca Pharmaceuticals LP; Pfizer; Roche

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Immunotherapy Strategies for the Treatment of NSCLC: An Update From Virtual Chicago

Authors: Karen Kelly, MD; Natasha Leighl, MD, MMSc, FRCPC, FASCO; Suresh S. Ramalingam, MD; Martin Reck, MD, PhD; Delvys Rodríguez-Abreu, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 10/22/2020

Valid for credit through: 10/22/2021, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799

Martin Reck, MD, PhD

Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer

Karen Kelly, MD

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)

Delvys Rodríguez-Abreu, MD

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Suresh S. Ramalingam, MD

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Martin Reck, MD, PhD

CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC)

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)

Delvys Rodríguez-Abreu, MD

Assessment Survey

Before you begin, please take this brief survey.

Page 1 of 10

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Karen Kelly, MD

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Suresh S. Ramalingam, MD

Martin Reck, MD, PhD

Delvys Rodríguez-Abreu, MD

Editor

Charlotte Warren

Course Director

Marina Chiara Garassino, MD

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

CME / ABIM MOC

Immunotherapy Strategies for the Treatment of NSCLC: An Update From Virtual Chicago

Target Audience and Goal Statement

Disclosures

Faculty

Karen Kelly, MD

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Suresh S. Ramalingam, MD

Martin Reck, MD, PhD

Delvys Rodríguez-Abreu, MD

Editor

Charlotte Warren

Course Director

Marina Chiara Garassino, MD

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Immunotherapy Strategies for the Treatment of NSCLC: An Update From Virtual Chicago

Contents of This CME Activity

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799

Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC)

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC)

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)

Assessment Survey